A theme concerning industry conditions in which the practical application of regenerative medicine is advancing through approvals in Japan and overseas for regenerative medicine products, CAR-T and gene therapy products, as well as authorization to conduct clinical trials and public health insurance coverage for gene-edited iPS cell-derived immune cells.